Galapagos NV (GLPG)
NASDAQ: GLPG · Real-Time Price · USD
32.25
+0.46 (1.45%)
Aug 15, 2025, 10:29 AM - Market open
Galapagos NV Employees
Galapagos NV had 704 employees as of December 31, 2024. The number of employees decreased by 419 or -37.31% compared to the previous year.
Employees
704
Change (1Y)
-419
Growth (1Y)
-37.31%
Revenue / Employee
$459,765
Profits / Employee
-$474,220
Market Cap
2.13B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 704 | -419 | -37.31% |
| Dec 31, 2023 | 1,123 | -215 | -16.07% |
| Dec 31, 2022 | 1,338 | 29 | 2.22% |
| Dec 31, 2021 | 1,309 | -180 | -12.09% |
| Dec 31, 2020 | 1,489 | 486 | 48.45% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
GLPG News
- 7 days ago - Galapagos Creates New Subscription Right Plan - GlobeNewsWire
- 9 days ago - Galapagos NV Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to GLPG5101 for the Treatment of Relapsed/Refractory Mantle Cell Lymphoma - GlobeNewsWire
- 22 days ago - Galapagos Bolster Leadership Team with Seasoned Life Sciences Executives to Accelerate Business Transformation - GlobeNewsWire
- 22 days ago - Galapagos Welcomes Seasoned Pharmaceutical Executives Dawn Svoronos and Jane Griffiths to Its Board of Directors - GlobeNewsWire
- 22 days ago - Galapagos Reports Half-Year 2025 Financial Results and Provides Second Quarter Business Update - GlobeNewsWire
- 7 weeks ago - Galapagos Appoints Aaron Cox as Chief Financial Officer - GlobeNewsWire
- 2 months ago - Galapagos Presented New Data at ICML 2025 From Cohort 3 of ATALANTA-1 in Relapsed/Refractory Indolent NHL Patients, Demonstrating High Complete Response and MRD Negativity Rates With CAR-T Candidate GLPG5101 - GlobeNewsWire
- 2 months ago - Galapagos to Present New ATALANTA-1 CAR-T Data at EHA 2025, Highlighting Low Toxicity and Rapid, Decentralized Delivery of Fresh, Early-Memory-Enriched GLPG5101 in R/R NHL - GlobeNewsWire